Gary S Leiserowitz
Overview
Explore the profile of Gary S Leiserowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCann C, Kamiyama N, Burgess D, Usher A, Fine J, Wilson M, et al.
J Adolesc Young Adult Oncol
. 2023 Aug;
13(2):288-292.
PMID: 37610879
A complication of cancer-directed therapy that often goes undiscussed is infertility. Although guidelines recommend addressing the possibility of infertility and fertility preservation approaches before initiating treatment, an internal review at...
2.
Bastola P, Leiserowitz G, Chien J
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740614
Protein quality control mechanisms play an important role in cancer progression by providing adaptive responses and morphologic stability against genome-wide copy number alterations, aneuploidy, and conformation-altering somatic mutations. This dependency...
3.
Mizenko R, Brostoff T, Rojalin T, Koster H, Swindell H, Leiserowitz G, et al.
J Nanobiotechnology
. 2021 Aug;
19(1):250.
PMID: 34419056
Background: Tetraspanin expression of extracellular vesicles (EVs) is often used as a surrogate for their detection and classification, a practice that typically assumes their consistent expression across EV sources. Results:...
4.
Chen H, Gotimer K, De Souza C, Tepper C, Karnezis A, Leiserowitz G, et al.
Gynecol Oncol
. 2020 Apr;
157(3):783-792.
PMID: 32253045
Objective: Cancer patient-derived organoids (PDOs) grow as three dimensional (3D) structures in the presence of extracellular matrix and have been found to represent the original tumor's genetic complexity. In addition,...
5.
Miyamoto S, Stroble C, Taylor S, Hong Q, Lebrilla C, Leiserowitz G, et al.
J Proteome Res
. 2017 Dec;
17(1):222-233.
PMID: 29207246
Protein glycosylation fingerprints are widely recognized as potential markers for disease states, and indeed differential glycosylation has been identified in multiple types of autoimmune diseases and several types of cancer....
6.
Nielsen A, Liyanage T, Leiserowitz G, Mayadev J
J Contemp Brachytherapy
. 2017 Jul;
9(3):216-223.
PMID: 28725244
Purpose: To propose an optimal perioperative pain management clinical care pathway for interstitial brachytherapy for gynecologic cancer based on our interdepartmental experience. Material And Methods: We conducted a retrospective review...
7.
Girda E, Huang E, Leiserowitz G, Smith L
Int J Gynecol Cancer
. 2017 Jul;
27(8):1701-1707.
PMID: 28683005
Objective: Patient-derived organoids (PDOs), used in multiple tumor types, have allowed evaluation of tumor characteristics from individual patients. This study aimed to assess the feasibility of applying PDO in vitro...
8.
Multispectral Optical Tweezers for Biochemical Fingerprinting of CD9-Positive Exosome Subpopulations
Carney R, Hazari S, Colquhoun M, Tran D, Hwang B, Mulligan M, et al.
Anal Chem
. 2017 Mar;
89(10):5357-5363.
PMID: 28345878
Extracellular vesicles (EVs), including exosomes, are circulating nanoscale particles heavily implicated in cell signaling and can be isolated in vast numbers from human biofluids. Study of their molecular profiling and...
9.
Leiserowitz G, Lin J, Tergas A, Cliby W, Bristow R
Int J Gynecol Cancer
. 2017 Mar;
27(4):675-683.
PMID: 28328580
Objectives: We performed a patterns-of-care study to characterize the types of patients with epithelial ovarian cancer (EOC) who received neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) using the National...
10.
Miyamoto S, Ruhaak L, Stroble C, Salemi M, Phinney B, Lebrilla C, et al.
J Proteome Res
. 2016 Aug;
15(9):3358-76.
PMID: 27500424
Ovarian cancer is a major cause of cancer mortality among women, largely due to late diagnosis of advanced metastatic disease. More extensive molecular analysis of metastatic ovarian cancer is needed...